Production technologies for monoclonal antibodies and their fragments.
about
Linkers Having a Crucial Role in Antibody-Drug ConjugatesMethods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Gene expression in Mammalian cells and its applicationsProduction and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor.Kinetic simulation of a centrifugal bioreactor for high population density hybridoma cultureIsolation of anti-CD22 Fv with high affinity by Fv display on human cells.Development of a novel mammalian cell surface antibody display platformComprehensive engineering of Escherichia coli for enhanced expression of IgG antibodiesGenetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.Host cell protein dynamics in the supernatant of a mAb producing CHO cell line.Cell culture processes for monoclonal antibody production.Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system.Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.A human anti-Pseudomonas aeruginosa serotype O6ad immunoglobulin G1 expressed in transgenic tobacco is capable of recruiting immune system effector function in vitro.Antibody therapeutics: isotype and glycoform selection.Glycosylation: impact, control and improvement during therapeutic protein production.Enhancing full-length antibody production by signal peptide engineering.Cultivation of Pichia pastoris carrying the scFv anti LDL (-) antibody fragment. Effect of preculture carbon source.Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.A high cell density transient transfection system for therapeutic protein expression based on a CHO GS-knockout cell line: process development and product quality assessment.High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus.An efficient route to bispecific antibody production using single-reactor mammalian co-culture.Ligation Independent Cloning of Polycistronic, Genetically Modified, HuMAb4D5-8 F (ab') 2, in Bacterial Plasmid.Expression of antibodies using single open reading frame (sORF) vector design: Demonstration of manufacturing feasibility.Ultra scale-down characterization of the impact of conditioning methods for harvested cell broths on clarification by continuous centrifugation-Recovery of domain antibodies from rec E. coli.Enhanced production of functional extracellular single chain variable fragment against HIV-1 matrix protein from Escherichia coli by sequential simplex optimization.Secretory production of single-chain antibody (scFv) in Brevibacillus choshinensis using novel fusion partner.Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis.'Zipbody' leucine zipper-fused Fab in E. coli in vitro and in vivo expression systems.Evolving trends in mAb production processes.Dual salt precipitation for the recovery of a recombinant protein from Escherichia coli.
P2860
Q26752763-B9991240-BAF7-4667-A09F-9D7696FE50FBQ26768654-09676801-AB30-42D4-BB84-C7EF26902A74Q27027017-DDC252F3-841C-4A8E-872A-598975B556FFQ30360451-119B32E8-4418-4478-BF40-4E9A7AAB8B2FQ30478843-6CA7B152-D161-4DF2-AEFA-65A8E29871E6Q33246226-8CFF8213-8E4E-4649-8A9C-11AA0DC9ED7CQ33661339-DCC557AD-3A1F-4B50-AB1E-C523DC52586FQ33763111-29436B58-0561-46FD-97B0-1E2ACA4E803FQ33892058-8B74947D-7516-41E3-A843-5B07DB1E13F9Q34085446-BA9DEDC2-96D0-4F22-8F98-9CC0991B96E6Q34125491-256C7874-A7A7-4E8A-9AA0-F4EB7556BC43Q34179215-4DD100BF-F377-4464-9D8A-C321CDE6A041Q34247760-A3268A57-28D2-4BDD-BC9D-E2DBD99BF72BQ36094806-1A78E89B-D5FD-4AA9-A7CC-B1DCA26E22C4Q36922260-931329FD-9B91-4F07-A1FB-2A44E33525C0Q38126913-D526524E-6BDC-408D-B2BA-71ADA9D2919BQ38749177-EDE7B54F-EB87-4948-8EF0-DC4F7E2F5BF6Q38753196-137A2193-6A04-4051-AF17-C9E5A364471CQ38755075-73B15930-9E21-4660-A068-6F45F15C4BBDQ38929054-BBEBC77D-F41D-4754-8EB1-8F88EF3CD625Q38954962-3A910361-F422-4C1C-AA18-45E6741821C6Q39428042-CD807752-6F43-4017-9BA3-59EA3CD2F69DQ39446212-CD63BA97-BE5D-47A3-9601-10FA5022407BQ40204575-29229397-47EB-4AC5-B04A-056B170ED818Q41675418-839B3DFD-6737-424C-98B1-66CE57D259B7Q41859825-0115129A-8297-44D0-8318-B0F0E4F9637FQ41899143-C208C49A-DEF5-420C-A867-22E3424EE4A5Q42120513-BBDB0C7A-CD75-4544-B0D7-60B2E3DB5B3AQ42215470-330970E3-FD98-4198-B1FD-8B813A6B2573Q43017498-5321B38E-1CA6-41E6-8701-8DDC7380BC30Q45869248-0E494C7E-DB23-4633-834F-B506E6F85841Q51503843-C444348C-30BF-4A43-8CC9-6AF1BBA55643Q52724995-6F4B0917-2D44-41EE-A11B-670B303A767AQ54360353-22E2071D-FC20-47CA-B211-B9514F7EBC6A
P2860
Production technologies for monoclonal antibodies and their fragments.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Production technologies for monoclonal antibodies and their fragments.
@ast
Production technologies for monoclonal antibodies and their fragments.
@en
type
label
Production technologies for monoclonal antibodies and their fragments.
@ast
Production technologies for monoclonal antibodies and their fragments.
@en
prefLabel
Production technologies for monoclonal antibodies and their fragments.
@ast
Production technologies for monoclonal antibodies and their fragments.
@en
P1476
Production technologies for monoclonal antibodies and their fragments.
@en
P2093
Dana C Andersen
Dorothea E Reilly
P304
P356
10.1016/J.COPBIO.2004.08.002
P577
2004-10-01T00:00:00Z